Pharmalot… Pharmalittle… The Weekend Nears
Make a commentBy Ed Silverman // October 22nd, 2010 // 7:06 am
Good morning, everyone. The end of the week is rapidly approaching and that usually means one thing - daydreaming about weekend plans. We expect to catch up on a few chores, but will spend most of our time entertaining the shortest of short people with a little bowling and ice cream, and a trip to the book store. What about you? A drive in the country to watch the leaves change? Toss a football? Pick a pumpkin? Walk your own official mascots? Whatever you do, have a good time and be safe. See you soon…
EMA Revises Stance On Genzyme’s Fabrazyme (Reuters)
Wyeth Must Disclose Earlier Effexor XR Patent Settlements (New Jersey Law Journal)
Amgen Exec Retires And Gets $400K Consulting Deal (SEC filing)
FDA Adds Heart Warning To HIV Drug Combo (Associated Press)
Roche And Biogen End Dispute Over Rituxan Follow-Ups (Reuters)
Alarms Over Radiation From Thyroid Cancer Patients (Associated Press)
New Zealand Allows Tracking Of Gov’t Funded Drug Applications (Pharma Times)
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, Amgen, Biogen, Effexor XR, Fabrazyme, Genzyme, George Morrow, HIV, Invirase, New Zealand, Norvir, Patents, Pfizer, Radiation, Rituxan, Roche, Thyroid Cancer, Wyeth